MacroGenics
MGNX
136 hedge funds and large institutions have $419M invested in MacroGenics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 18 closing their positions.
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
12% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 42
12% more capital invested
Capital invested by funds: $375M → $419M (+$43.7M)
3.51% more ownership
Funds ownership: 91.01% → 94.51% (+3.5%)
2% more funds holding
Funds holding: 133 → 136 (+3)
45% less call options, than puts
Call options by funds: $505K | Put options by funds: $921K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$10.3M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$4.51M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$3.79M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.55M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$5.55M |
| 2 |
Millennium Management
New York
|
-$5.14M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.06M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.34M |
MGNX Hedge Fund Activity: Q1 2023 in Review
136 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q1 2023, worth a combined $419M — up 12% from $375M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MGNX positions and 18 closed out — a net gain of 3 holders — while 47 added to existing stakes and 42 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $10.3M. The largest seller was Wasatch Advisors, cutting an estimated $5.55M.
- 136 institutional investors held MacroGenics (MGNX) as of Q1 2023, up from 133 in Q4 2022.
- Funds reported $419M of MacroGenics stock for Q1 2023, up 12% quarter-over-quarter.
- 21 funds opened new MacroGenics positions in Q1 2023 and 18 closed out, a net change of +3 holders.
- The largest MacroGenics buyer in Q1 2023 was Frazier Life Sciences Management, an estimated $10.3M added.
- The largest MacroGenics seller in Q1 2023 was Wasatch Advisors, an estimated $5.55M sold.
Based on aggregated 13F filings for Q1 2023.